Merck completed the acquisition of Verona Pharma for $10bn.

Merck, a healthcare company, completed the acquisition of Verona Pharma, a biopharmaceutical company, for $10bn. “This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ability to execute on our science-led and value-driven business development strategy. Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders. This novel, first-in-class treatment addresses an important unmet need for COPD patients persistently symptomatic based on its unique combination of bronchodilatory and non-steroidal anti-inflammatory effects. We look forward to welcoming the talented Verona Pharma team to Merck,” Robert M. Davis, Merck Chairman and CEO.